CN109645501A - A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence - Google Patents
A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence Download PDFInfo
- Publication number
- CN109645501A CN109645501A CN201910033563.3A CN201910033563A CN109645501A CN 109645501 A CN109645501 A CN 109645501A CN 201910033563 A CN201910033563 A CN 201910033563A CN 109645501 A CN109645501 A CN 109645501A
- Authority
- CN
- China
- Prior art keywords
- defaecation
- galactooligosaccharide
- flatulence
- composition
- oligoisomaltose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000021255 galacto-oligosaccharides Nutrition 0.000 title claims abstract description 60
- 150000003271 galactooligosaccharides Chemical class 0.000 title claims abstract description 60
- 206010016766 flatulence Diseases 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000009467 reduction Effects 0.000 title abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 25
- 235000018291 probiotics Nutrition 0.000 claims abstract description 25
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 20
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 210000000936 intestine Anatomy 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 7
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 6
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 235000006468 Thea sinensis Nutrition 0.000 claims description 5
- 235000019864 coconut oil Nutrition 0.000 claims description 5
- 239000003240 coconut oil Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- 241000186012 Bifidobacterium breve Species 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 18
- 230000013872 defecation Effects 0.000 abstract description 9
- 206010006326 Breath odour Diseases 0.000 abstract description 4
- 208000032139 Halitosis Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 230000008855 peristalsis Effects 0.000 abstract description 3
- 230000003833 cell viability Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 22
- 238000012360 testing method Methods 0.000 description 18
- 235000013406 prebiotics Nutrition 0.000 description 10
- 230000036039 immunity Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 230000000675 anti-caries Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to technical field of health care food, and in particular to a kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence.Defaecation provided by the invention and the galactooligosaccharide composition for reducing flatulence are made of following component and its weight percent: oligofructose 2.5~25%, oligoisomaltose 1~30%, probiotics 0.5~7%, edible vegetable oil 1~8%, galactooligosaccharide 30~95%.Defaecation provided by the invention and reduce flatulence galactooligosaccharide composition can relax bowel and defecation, improve and prevent constipation, while also have the effect of reduction flatulence, and it can build up resistance, promote cell viability, accelerate enterogastric peristalsis, stool odor and halitosis are eliminated, is had a good application prospect.
Description
Technical field
The invention belongs to technical field of health care food, and in particular to a kind of galactooligosaccharide combination of defaecation and reduction flatulence
Object and its application.
Background technique
Constipation is to endanger the common disease of human health, and chronic functional constipation is mostly by old, postoperative gas consumption of weak and postpartum
Blood trouble, intestine-dryness due to consumption of fluid cause to defecate unsmooth be difficult to walk and cause.Illness rate of the constipation in crowd is up to 27%, but only one is small
Part constipation person can go to a doctor, and constipation can influence the people of each age group, and women is more than male, the elderly's extra green, prime of life, because just
Secret disease incidence is high, and the cause of disease is complicated, and patient often has manifold vexations, and will affect quality of life when constipation is serious.
Constipation often shows themselves in that awareness of defecation is few, and bowel frequency is also few；Defecation is difficult, laborious；Defecation is unsmooth；Dry and hard excrement, it is hard just, row
Just not clean sense；Constipation is with abdominal pain or abdominal discomfort, and some patientss are also with spirit such as insomnia, agitation, dreaminess, depression and anxiety
Mental handicape.Since constipation is a kind of more universal symptom, symptoms of varying severity, most people usually do not go it is special comprehend,
Think that constipation is not disease, do not have to treatment, but the harm of actually constipation is very big, the Alarm sign of constipation include hematochezia, anaemia,
Syntexis, fever, melena, abdominal pain etc..It is cured the disease according to traditional Chinese medicine and works as the principle for asking it, preferably with nourishing qi and blood in treatment, ease constipation is logical
Just it makes laws, chronic functional constipation can be made to achieve the purpose that sample is part-time.Currently, being improved for bowel problems such as constipation
Used health care product is mostly to be made by raw material of a variety of prebiotics, for example, Chinese patent CN1731938B discloses a kind of benefit
Raw member composition, the composition are composed of oligofructose and galactooligosaccharide by weight 0.5~2, and the composition can
The relevant illness of effective controlling inflammation property enteropathy and diarrhea constipation etc., but the composition effect curative effect is slower, needs for a long time
Using can just there is remarkable result.
Chinese patent application CN107981359A discloses a kind of prebiotic compositions, and the composition includes oligomeric gala
Sugar, oligofructose and isomerizing lactose, and the weight fraction ratio of the galactooligosaccharide, oligofructose, isomerizing lactose is (5
~10): (0.5~1.5): (0.5~1.5), the composition can enhance immunity of organisms and comprehensive function, enteron aisle promoted to disappear
Change, but for constipation patient especially baby, still because part easily forms mouth because intestinal portion beneficial bacteria lacks
It is smelly, make us very headache.
Therefore, the composition for cooperateing with prebiotic effect to obtain using prebiotics compounding, it is easy to form for enteron aisle act on it is single,
Defecating feces excretion is weak, enteron aisle is easily uncomfortable and because intestinal portion beneficial bacteria lacks the problems such as easily forming halitosis, is badly in need of a kind of full side
Position effect, and significant composition comes out effect comprehensively.
Summary of the invention:
In view of the deficiencies of the prior art, the purpose of the present invention is to provide the galactooligosaccharides of a kind of defaecation and reduction flatulence
Composition and its application, defaecation provided by the invention and reduce flatulence galactooligosaccharide composition can relax bowel and defecation, improve
And prevent constipation, matched probiotics can cultivate correct bowl evacuation habit；And it is compounded, is added prebiotic by a variety of prebiotics
Bacterium and essential oil can not only effectively and quickly achieve the effect that defaecation reduces flatulence, and can build up resistance, and promote thin
Born of the same parents' vigor accelerates enterogastric peristalsis, eliminates stool odor and halitosis, has a good application prospect.
Technical scheme is as follows:
A kind of galactooligosaccharide composition of defaecation and reduction flatulence, is made of following component and its weight percent:
Oligofructose 2.5~25%, oligoisomaltose 1~30%, probiotics 0.5~7%, edible vegetable oil 1~
8%, galactooligosaccharide 30~95%.
Further, the galactooligosaccharide composition of the defaecation and reduction flatulence, by following component and its weight percent
Array at:
Oligofructose 15%, oligoisomaltose 18%, probiotics 3.5%, edible vegetable oil 4.5%, galactooligosaccharide
59%.
Further, the oligomeric fruit that the chain by the degree of polymerization 3~5 that the oligofructose contains up to 95% weight forms
Sugar；The oligoisomaltose contains the oligoisomaltose of up to 90% weight being made of the chain of the degree of polymerization 2~10；It is described
The galactooligosaccharide that the chain for being 2~7 by the degree of polymerization that galactooligosaccharide contains up to 95% weight forms.
Further, the probiotics be lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, Lactobacillus rhamnosus,
One of lactobacillus fermenti, bifidobacterium breve are a variety of.
Further, the edible vegetable oil include one of olive oil, Purple Perilla Seed Oil, coconut oil, Seed of Camellia Sinensis oil or
It is several.
Another object of the present invention is to provide the defaecations and the galactooligosaccharide composition for reducing flatulence to prepare
Defaecation reduces flatulence and/or protects the application in intestines shield stomach health food.
Compared with prior art, beneficial effects of the present invention are as follows:
(1) in the galactooligosaccharide composition of defaecation provided by the invention and reduction flatulence, by galactooligosaccharide, oligomeric fruit
Sugar, oligoisomaltose compounding, resulting composition can not only effectively facilitate proliferation of probiotics, promote human consumption to absorb, subtract
Enteron aisle balance is adjusted, reduces enterogenous endotoxin, moreover it is possible to promote micro- with the generation of inhibition enteral corrupt substance, inhibition bacterial growth less
The absorption and utilization of secondary element improve passive protective physical fitness and immunity, meanwhile, the smelly element of intracorporal excrement can be reduced and remove,
Reduce just smelly and halitosis phenomenon.
(2) in the galactooligosaccharide composition of defaecation provided by the invention and reduction flatulence, probiotics and a variety of prebiotics
Combination, not only effectively facilitates the activation of probiotics, while can also promote blood circulation, and accelerates enterogastric peristalsis, helps to eat
Object digestion has the function of good defaecation and reduces flatulence.
(3) in the galactooligosaccharide composition of defaecation provided by the invention and reduction flatulence, a small amount of edible vegetable oil is added,
Moisture can be effectively dispelled, is conducive to intestinal health movement, and the synergistic effect with three kinds of prebiotics, enteron aisle can be moistened, led to
Just, abdominal distension diarrhea is reduced, has the function of good shield intestines shield stomach, moreover, the addition of edible vegetable oil, moreover it is possible to effective
Body inflammatory is reduced, human body appetite is improved.
(4) defaecation provided by the invention and the galactooligosaccharide composition of flatulence is reduced, prebiotics and probiotics and eaten
Vegetable oil compounding, greatly reduces the residual of intestinal harmful bacillus, improves defaecation and reduces the effect of flatulence, moreover,
The resistivity of stomach and body can also be enhanced, enteron aisle is protected, reduce the generation of intestines problem, before there is good application
Scape.
Galactooligosaccharide: mainly using its can by all Bifidobacterium selective uses without be proliferated harmful bacteria characteristic,
Significant proliferation Bifidobacterium cannot be digested, and go directly enteron aisle, improve constipation, be conducive to pre- anti-caries, promote calcium and
The mineral absorptions such as magnesium；
Oligofructose: indigestibility has and the characteristic of water-soluble dietary fiber maintenance intestines and stomach function, raising enteron aisle bifid
Bacillus number significantly inhibits harmful bacteria breeding, reducing blood lipid, serum cholesterol, relax bowel and defecation；
Oligoisomaltose: main intestinal bifidobacteria number, the smelly cellulose content of reduction excrement, the reduction total gallbladder of serum of improving is consolidated
Alcohol, physiological energy value are low.
Lactobacillus acidophilus: adjustment intestinal flora balance inhibits harmful microbe proliferation in enteron aisle, gastrointestinal function can be made to lose
The crowd of tune restores normal the gut flora；Mitigate lactose intolerance, improve body immunity, mitigates respiratory tract infection, prevented
Quick disease etc..
Animal bifidobacteria: inhibiting spoilage organisms growth, promote the degradation and absorption of food, and " lactose intolerance " trouble can be improved
Person can synthesize vitamin B1, B2, B6 and K etc. to the utilization rate of dairy products, can treat chronic diarrhea, improve body immunity.
Bifidobacterium lactis: can treat chronic diarrhea, improve body immunity, have and resist acute and persistent diarrhea protection
Effect, may be decreased the disease incidence of respiratory tract infection.
Lactobacillus rhamnosus: balance and improve gastrointestinal function, enhance human autoimmune's ability, promote Bifidobacterium and
Diarrhea is treated in lactobacillus acidophilus growth and effect, prevention and help, and preventing respiratory tract infection, pre- anti-caries are pre- hypo-allergenic, to controlling
Treating physiologic jaundice has certain effect.
Lactobacillus fermenti: can be improved body immunity and intestinal health, have good therapeutic effect to lactation mastitis.
Bifidobacterium breve: can improve intestinal environment, inhibit the growth of intestinal harmful bacillus, improve immunity, prevention is just
It is secret.
Specific embodiment
The specific embodiment of form by the following examples makees further specifically above content of the invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to following embodiment.
Embodiment 1, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligofructose 2.5%, oligoisomaltose 1%, probiotics 0.5%, edible vegetable oil 1%, galactooligosaccharide
95%.
Embodiment 2, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligofructose 25%, oligoisomaltose 30%, probiotics 7%, edible vegetable oil 8%, galactooligosaccharide 30%.
Embodiment 3, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligofructose 15%, oligoisomaltose 18%, probiotics 3.5%, edible vegetable oil 4.5%, galactooligosaccharide
59%.
The probiotics is made of bifidobacterium lactis, Lactobacillus rhamnosus by weight 6:5.
The edible vegetable oil is made of coconut oil, Seed of Camellia Sinensis oil by weight 3:2.
Embodiment 4, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligofructose 20%, oligoisomaltose 16%, probiotics 5.5%, edible vegetable oil 6.5%, galactooligosaccharide
52%.
The probiotics is made of Lactobacillus rhamnosus, lactobacillus fermenti, bifidobacterium breve by weight 6:3:2.
The edible vegetable oil is made of Purple Perilla Seed Oil, tea oil, olive oil by weight 4:3:2.
Comparative example 1, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligoisomaltose 33%, probiotics 3.5%, edible vegetable oil 4.5%, galactooligosaccharide 59%.
The probiotics is made of bifidobacterium lactis, Lactobacillus rhamnosus by weight 6:5.
The edible vegetable oil is made of coconut oil, Seed of Camellia Sinensis oil by weight 3:2.
Comparative example 1 is substantially the same manner as Example 3, and difference is, oligofructose is replaced with identical weight hundred in comparative example 1
The oligoisomaltose of score.
Comparative example 2, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligofructose 18.5%, oligoisomaltose 18%, edible vegetable oil 4.5%, galactooligosaccharide 59%.
The edible vegetable oil is made of coconut oil, Seed of Camellia Sinensis oil by weight 3:2.
Comparative example 2 is substantially the same manner as Example 3, and difference is, probiotics is replaced with identical weight percentage in comparative example 2
Several oligofructose.
Comparative example 3, a kind of defaecation and the galactooligosaccharide composition for reducing flatulence
The defaecation and the galactooligosaccharide composition for reducing flatulence, are made of following component and its weight percent:
Oligofructose 15%, oligoisomaltose 18%, probiotics 8%, galactooligosaccharide 59%.
The probiotics is made of bifidobacterium lactis, Lactobacillus rhamnosus by weight 6:5.
Comparative example 3 is substantially the same manner as Example 3, and difference is, edible vegetable oil is replaced with identical weight in comparative example 3
The probiotics of percentage.
Test example one, defaecation performance test
1, test material: defaecation prepared by Examples 1 to 4 and comparative example 1~3 and the galactooligosaccharide combination for reducing flatulence
Object.
2, subjects: kunming mice 180, half male and half female.
3, by 180 kunming mices, 9 groups, every group 20 test method: are randomly divided into after weighing.Test before stop eating for 24 hours to
Water, by 10mg/kg compound fragrant promise vinegar suspension oral gavage replicates Constipation Model to each group mouse in addition to blank group.After modeling 30min,
The suspension of model group stomach-filling water and starch；Residue defaecation and reduction that respectively prepared by stomach-filling Examples 1 to 4 and comparative example 1~3
The suspension of the galactooligosaccharide composition of flatulence is denoted as Examples 1 to 4 group and 1~3 group of comparative example by 4g/kg weight respectively；
Eosin is added in the suspension that all experiments are used as indicator.Then recording the red efflux time just of first grain, (head can be by
Eosin is designated as red), defecation grain number, character and dry weight in 6h.
4, test result: function test the results are shown in Table 1 data.
1 Functional Test Data of table
As shown in Table 1, compared with model group and 1~3 group of comparative example, the first just time of Examples 1 to 4 group is obviously shortened,
6h defecation increased significantly, and excrement without it is stiff smelly phenomena such as occur, differ less compared with the control group, wherein embodiment 3
Effect is most obvious, is highly preferred embodiment of the present invention.Benefit is added in three kinds of prebiotic compositions it can be seen from 1 test data of table
Raw bacterium and edible vegetable oil, the synergistic effect of several components effectively facilitate digestion, promote defecation, and constipation significantly reduces.
Test example two reduces flatulence performance test
1, test material: defaecation prepared by Examples 1 to 4 and comparative example 1~3 and the galactooligosaccharide combination for reducing flatulence
Object.
2, subjects: kunming mice 140,25~30g of weight, half male and half female.
3, test method: by 140 kunming mices, mouse is divided into 7 groups at random, every group 20, (mouse is raised 2~3
It, is familiar with environment, and the galactooligosaccharide by defaecation and reduction flatulence prepared by Examples 1 to 4 and comparative example 1~3 combines respectively
Stomach-filling suspension is made in object crushing, groups of animals fasting 12 hours before testing, therebetween free water), each test group is by weight
2% stomach-filling volume orally administration tested material dissects mouse, carries out swollen intestines volume determination 2 hours after stomach-filling.
4, test result: flatulence performance test results are reduced and are shown in Table 2.
Table 2 reduces flatulence performance test data
| Group | Dosage (g/kg weight) | Swollen intestines volume (cm3) |
| Example 1 group | 4 | 2.82±0.21 |
| 2 groups of embodiment | 4 | 2.79±0.35 |
| 3 groups of embodiment | 4 | 2.73±0.24 |
| 4 groups of embodiment | 4 | 2.76±0.19 |
| 1 group of comparative example | 4 | 4.05±0.56 |
| 2 groups of comparative example | 4 | 4.08±0.48 |
| 3 groups of comparative example | 4 | 4.22±0.28 |
As shown in Table 2, compared with 1~3 group of comparative example, the swollen intestines volume of Examples 1 to 4 group is obviously reduced, and embodiment 3
The effect of group is best, and therefore, embodiment 3 is in comparison highly preferred embodiment of the present invention probiotics is not added to flatulence
Reducing influences maximum, shows that the addition of probiotics can effectively reduce the generation of flatulence, and several components compound, and improve flatulence
The effect of reduction.
Test example three, clinical test
1, test material: defaecation prepared by Examples 1 to 4 and comparative example 1~3 and the galactooligosaccharide combination for reducing flatulence
Object.
2, subjects: selecting 50~80 years old 70 people of constipation patient, and 70 constipation patients have constipation, flatulence, abdominal pain, appetite
70 patients are divided into 7 groups at random by depressed symptom.
3, test method: 7 groups of patients take composition prepared by Examples 1 to 4 and comparative example 1~3 respectively, take orally each
3g, 2 times a day.Normal diet after continuously taking 3 days, observes clinical picture.
4, test result.Test result is shown in Table 3.
3 clinical test phenomenon of table
As shown in Table 3, compared with 1~3 group of comparative example, Examples 1 to 4 has apparent defaecation, reduces flatulence, shield intestines shield
Stomach enhances stomach immunity and appetitive effect, wherein the effect that 3 groups of embodiment is best, and therefore, embodiment 3 is this hair
Bright most preferred embodiment.Test result shows that defaecation prepared by the present invention and the galactooligosaccharide composition for reducing flatulence have
Good defaecation, except flatulence, protection enteron aisle and promote digestion, orectic effect, preparation shield enteron aisle, promote digestion, defaecation protect
It has a good application prospect in strong product.
The above-described embodiments merely illustrate the principles and effects of the present invention, and is not intended to limit the present invention.It is any ripe
The personage for knowing this technology all without departing from the spirit and scope of the present invention, carries out modifications and changes to above-described embodiment.Cause
This, institute is complete without departing from the spirit and technical ideas disclosed in the present invention by those of ordinary skill in the art such as
At all equivalent modifications or change, should be covered by the claims of the present invention.
Claims (6)
1. a kind of defaecation and the galactooligosaccharide composition for reducing flatulence, which is characterized in that by following component and its weight percent
Array at:
It is oligofructose 2.5~25%, oligoisomaltose 1~30%, probiotics 0.5~7%, edible vegetable oil 1~8%, low
Poly- galactolipin 30~95%.
2. defaecation as described in claim 1 and the galactooligosaccharide composition for reducing flatulence, which is characterized in that by following component
And its weight percent composition:
Oligofructose 15%, oligoisomaltose 18%, probiotics 3.5%, edible vegetable oil 4.5%, galactooligosaccharide 59%.
3. defaecation as claimed in claim 1 or 2 and the galactooligosaccharide composition for reducing flatulence, which is characterized in that described low
Fructooligosaccharides contains the oligofructose of up to 95% weight being made of the chain of the degree of polymerization 3~5；The oligoisomaltose contains height
Up to the oligoisomaltose of 90% weight being made of the chain of the degree of polymerization 2~10；The galactooligosaccharide contains up to 95% weight
The galactooligosaccharide that the chain for being 2~7 by the degree of polymerization of amount forms.
4. defaecation as claimed in claim 1 or 2 and the galactooligosaccharide composition for reducing flatulence, which is characterized in that the benefit
Raw bacterium be lactobacillus acidophilus, animal bifidobacteria, bifidobacterium lactis, Lactobacillus rhamnosus, lactobacillus fermenti, in bifidobacterium breve
It is one or more.
5. defaecation as claimed in claim 1 or 2 and the galactooligosaccharide composition for reducing flatulence, which is characterized in that the food
It include one or more of olive oil, Purple Perilla Seed Oil, coconut oil, Seed of Camellia Sinensis oil with vegetable oil.
6. defaecation as claimed in any one of claims 1 to 5 and the galactooligosaccharide composition for reducing flatulence are preparing defaecation, are subtracting
Application in few flatulence and/or shield intestines shield stomach health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910033563.3A CN109645501A (en) | 2019-01-14 | 2019-01-14 | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910033563.3A CN109645501A (en) | 2019-01-14 | 2019-01-14 | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109645501A true CN109645501A (en) | 2019-04-19 |
Family
ID=66119503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910033563.3A Withdrawn CN109645501A (en) | 2019-01-14 | 2019-01-14 | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109645501A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718289A (en) * | 2019-01-07 | 2019-05-07 | 云浮市新金山生物科技股份有限公司 | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases |
| CN112741334A (en) * | 2019-10-29 | 2021-05-04 | 内蒙古伊利实业集团股份有限公司 | Prebiotic compositions, and uses thereof |
| CN115644457A (en) * | 2022-10-26 | 2023-01-31 | 杭州衡美食品科技有限公司 | Preparation method and application of composition for improving intestinal health |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
| CN101496822A (en) * | 2009-02-18 | 2009-08-05 | 上海谱莱生物技术有限公司 | Composite probiotics micro-ecological formulation and preparation method |
| CN107788315A (en) * | 2017-11-27 | 2018-03-13 | 威海养经堂医药科技有限公司 | A kind of Cordyceps militaris LBP-X solid beverage |
| CN109170909A (en) * | 2018-10-10 | 2019-01-11 | 河北畅然生物科技有限公司 | A kind of compound probiotic and prebiotic compositions and preparation method thereof improving constipation |
-
2019
- 2019-01-14 CN CN201910033563.3A patent/CN109645501A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
| CN101496822A (en) * | 2009-02-18 | 2009-08-05 | 上海谱莱生物技术有限公司 | Composite probiotics micro-ecological formulation and preparation method |
| CN107788315A (en) * | 2017-11-27 | 2018-03-13 | 威海养经堂医药科技有限公司 | A kind of Cordyceps militaris LBP-X solid beverage |
| CN109170909A (en) * | 2018-10-10 | 2019-01-11 | 河北畅然生物科技有限公司 | A kind of compound probiotic and prebiotic compositions and preparation method thereof improving constipation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718289A (en) * | 2019-01-07 | 2019-05-07 | 云浮市新金山生物科技股份有限公司 | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases |
| CN112741334A (en) * | 2019-10-29 | 2021-05-04 | 内蒙古伊利实业集团股份有限公司 | Prebiotic compositions, and uses thereof |
| CN115644457A (en) * | 2022-10-26 | 2023-01-31 | 杭州衡美食品科技有限公司 | Preparation method and application of composition for improving intestinal health |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111972670A (en) | Composition for relaxing bowel, solid beverage and application | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| CN107455744A (en) | A kind of fementative composition ferment and preparation method thereof in vivo | |
| CN111035014A (en) | Probiotic preparation and preparation method thereof | |
| CN107467677A (en) | A kind of compound nutritional product for relaxing bowel, maintaining intestinal health and preparation method and application | |
| CN104524110A (en) | Traditional Chinese medicine composition with functions of tonifying spleen and clearing damp | |
| CN108477617A (en) | A kind of probiotic powder and preparation method thereof to relax bowel | |
| CN114146101B (en) | Application of bifidobacterium animalis subspecies lactis BLa80 in preparation of medicines or foods for regulating intestinal motility | |
| CN109619540A (en) | A kind of probiotic composition and its preparation method and application with functions of loosening bowel relieving constipation | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN107496850A (en) | A kind of formula for adjusting enteral microecological formulation and application | |
| CN109645501A (en) | A kind of galactooligosaccharide composition and its application of defaecation and reduction flatulence | |
| US10369184B2 (en) | Composition and use thereof in manufacture of product for improving intestinal function | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| CN109718289A (en) | A kind of galactooligosaccharide prebiotic compositions treating or preventing enterogastric diseases | |
| CN102657794A (en) | Traditional Chinese medicine for prevention and treatment of pullorum disease, preparation method thereof and feed | |
| EP3551207A1 (en) | A fermented composition comprising a high content of one or more lactic acid bacterial strains and a method for making the composition and use thereof | |
| CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
| CN116076736B (en) | Anti-claustrophobic stomach nourishing composition and application thereof | |
| CN107118981A (en) | A kind of probiotics preparation and its application for being used to nurse one's health enteric microorganism environment | |
| CN107095308A (en) | A kind of probiotics preparation and its application | |
| CN114287633A (en) | Probiotic composition containing cranberry and application of probiotic composition in resisting helicobacter pylori | |
| CN108938789A (en) | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide | |
| CN105995443B (en) | Infant intestine-benefiting nutritional rice flour and preparation method thereof | |
| CN111528486A (en) | Composition containing lactoferrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190419 |
|
| WW01 | Invention patent application withdrawn after publication |